FibroBiologics (FBLG) Other Non-Current Assets (2025 - 2026)
FibroBiologics' (FBLG) quarterly Other Non-Current Assets came in at $48000.0 in Q2 2026, little changed on a YoY basis from $48000.0 in Q2 2025, and little changed quarter-over-quarter from $48000.0 in Q1 2026.
Powered by 
Analysis
FibroBiologics (FBLG) Other Non-Current Assets (2025 - 2026) Analysis & Trends
FibroBiologics (FBLG) has reported Other Non-Current Assets for 2 consecutive years, with $48000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Other Non-Current Assets changed 0.0% year-over-year to $48000.0; the trailing twelve-month figure through Jun 2026 stood at $48000.0 (changed 0.0% YoY), and the FY2025 full-year result was $48000.0, changed N/A from the prior year.
- Other Non-Current Assets held at $48000.0 in Q2 2026 per FBLG's latest filing, from $48000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $48000.0 in Q2 2025 and bottomed at $48000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn | 284,000.00 |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 37.71 Mn |
| 3 | Iovance Biotherapeutics | 3.64 Bn | 3.35 Bn | 55.72 Mn | 6.43 Mn |
| 4 | Legend Biotech | 3.54 Bn | 2.58 Bn | 251.50 Mn | 25.50 Mn |
| 5 | uniQure | 2.98 Bn | 2.98 Bn | 5.49 Mn | 4.54 Mn |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | 7.86 Mn |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 708,000.00 |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 146.15 Mn |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 233,000.00 |
| 10 | FibroBiologics | 10.66 Mn | 10.66 Mn | - | 48,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 48,000.00 |
| Mar 31, 2026 | 48,000.00 |
| Dec 31, 2025 | 48,000.00 |
| Sep 30, 2025 | 48,000.00 |
| Jun 30, 2025 | 48,000.00 |